A cysteine for glycine substitution at position 175 in an α1 (i) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta

Mary Wirtz, Velidi H. Rao, Robert W. Glanville, Michael E. Labhard, Petrus J. Pretorius, W. Nancy de Vries, Wouter J. de Wet, David W. Hollister

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The molecular basis for Osteogenesis Imperfecta in a large kindred with a highly variable phenotype was identified by sequencing the mutant pro α 1 (I) protein, cDNA and genomic DNA from the proband. Fibroblasts from different affected individuals all synthesize both normal Type I procollagen molecules and abnormal Type I procollagen molecules in which one or both proα 1(I) chain(s) contain a cy steine residue within the triple helical domain. Protein studies of the proband localized the mutant cysteine residue to the α 1 (I) CB 8 peptide.1 We now report that cysteine has replaced glycine at triple helical residue 175 disrupting the invariant Gly-X-Y structural motif required for perfect triple helix formation. The consequences include post-translational overmodification, decreased thermal stability, and delayed secretion of mutant molecules.2 The highly variable phenotype in the present kindred cannot be explained solely on the basis of the cysteine for glycine substitution but will require further exploration.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalConnective Tissue Research
Volume29
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Osteogenesis Imperfecta
Collagen Type I
Glycine
Cysteine
Substitution reactions
Phenotype
Molecules
Fibroblasts
Proteins
Thermodynamic stability
Complementary DNA
Hot Temperature
DNA

Keywords

  • Cysteine
  • Osteogenesis Imperfecta
  • Type I collagen

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Orthopedics and Sports Medicine
  • Rheumatology
  • Immunology
  • Nephrology

Cite this

A cysteine for glycine substitution at position 175 in an α1 (i) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta. / Wirtz, Mary; Rao, Velidi H.; Glanville, Robert W.; Labhard, Michael E.; Pretorius, Petrus J.; de Vries, W. Nancy; de Wet, Wouter J.; Hollister, David W.

In: Connective Tissue Research, Vol. 29, No. 1, 1993, p. 1-11.

Research output: Contribution to journalArticle

Wirtz, Mary ; Rao, Velidi H. ; Glanville, Robert W. ; Labhard, Michael E. ; Pretorius, Petrus J. ; de Vries, W. Nancy ; de Wet, Wouter J. ; Hollister, David W. / A cysteine for glycine substitution at position 175 in an α1 (i) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta. In: Connective Tissue Research. 1993 ; Vol. 29, No. 1. pp. 1-11.
@article{3b50651dafae4a4bbc10d76de3b74503,
title = "A cysteine for glycine substitution at position 175 in an α1 (i) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta",
abstract = "The molecular basis for Osteogenesis Imperfecta in a large kindred with a highly variable phenotype was identified by sequencing the mutant pro α 1 (I) protein, cDNA and genomic DNA from the proband. Fibroblasts from different affected individuals all synthesize both normal Type I procollagen molecules and abnormal Type I procollagen molecules in which one or both proα 1(I) chain(s) contain a cy steine residue within the triple helical domain. Protein studies of the proband localized the mutant cysteine residue to the α 1 (I) CB 8 peptide.1 We now report that cysteine has replaced glycine at triple helical residue 175 disrupting the invariant Gly-X-Y structural motif required for perfect triple helix formation. The consequences include post-translational overmodification, decreased thermal stability, and delayed secretion of mutant molecules.2 The highly variable phenotype in the present kindred cannot be explained solely on the basis of the cysteine for glycine substitution but will require further exploration.",
keywords = "Cysteine, Osteogenesis Imperfecta, Type I collagen",
author = "Mary Wirtz and Rao, {Velidi H.} and Glanville, {Robert W.} and Labhard, {Michael E.} and Pretorius, {Petrus J.} and {de Vries}, {W. Nancy} and {de Wet}, {Wouter J.} and Hollister, {David W.}",
year = "1993",
doi = "10.3109/03008209309061961",
language = "English (US)",
volume = "29",
pages = "1--11",
journal = "Connective Tissue Research",
issn = "0300-8207",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A cysteine for glycine substitution at position 175 in an α1 (i) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta

AU - Wirtz, Mary

AU - Rao, Velidi H.

AU - Glanville, Robert W.

AU - Labhard, Michael E.

AU - Pretorius, Petrus J.

AU - de Vries, W. Nancy

AU - de Wet, Wouter J.

AU - Hollister, David W.

PY - 1993

Y1 - 1993

N2 - The molecular basis for Osteogenesis Imperfecta in a large kindred with a highly variable phenotype was identified by sequencing the mutant pro α 1 (I) protein, cDNA and genomic DNA from the proband. Fibroblasts from different affected individuals all synthesize both normal Type I procollagen molecules and abnormal Type I procollagen molecules in which one or both proα 1(I) chain(s) contain a cy steine residue within the triple helical domain. Protein studies of the proband localized the mutant cysteine residue to the α 1 (I) CB 8 peptide.1 We now report that cysteine has replaced glycine at triple helical residue 175 disrupting the invariant Gly-X-Y structural motif required for perfect triple helix formation. The consequences include post-translational overmodification, decreased thermal stability, and delayed secretion of mutant molecules.2 The highly variable phenotype in the present kindred cannot be explained solely on the basis of the cysteine for glycine substitution but will require further exploration.

AB - The molecular basis for Osteogenesis Imperfecta in a large kindred with a highly variable phenotype was identified by sequencing the mutant pro α 1 (I) protein, cDNA and genomic DNA from the proband. Fibroblasts from different affected individuals all synthesize both normal Type I procollagen molecules and abnormal Type I procollagen molecules in which one or both proα 1(I) chain(s) contain a cy steine residue within the triple helical domain. Protein studies of the proband localized the mutant cysteine residue to the α 1 (I) CB 8 peptide.1 We now report that cysteine has replaced glycine at triple helical residue 175 disrupting the invariant Gly-X-Y structural motif required for perfect triple helix formation. The consequences include post-translational overmodification, decreased thermal stability, and delayed secretion of mutant molecules.2 The highly variable phenotype in the present kindred cannot be explained solely on the basis of the cysteine for glycine substitution but will require further exploration.

KW - Cysteine

KW - Osteogenesis Imperfecta

KW - Type I collagen

UR - http://www.scopus.com/inward/record.url?scp=0027520602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027520602&partnerID=8YFLogxK

U2 - 10.3109/03008209309061961

DO - 10.3109/03008209309061961

M3 - Article

C2 - 8339541

AN - SCOPUS:0027520602

VL - 29

SP - 1

EP - 11

JO - Connective Tissue Research

JF - Connective Tissue Research

SN - 0300-8207

IS - 1

ER -